No results for ‘’
IOL Chemicals & Pharmaceuticals Ltd
₹194.31
(8.10%)
Thu, 17 Sept 2026, 09:59 pm
Process Industries
Chemicals: Specialty
24.5KIOL Chemicals & Pharmaceuticals PB Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 15.53 | 11.94 | 12.18 | 15.06 | 13.31 | 40.74 | 15.95 | 0 | 0 | 76.08 | 16.13 | 4.52 | 2.78 | 7.22 | 12.39 | 11.94 | 78.93 | 17.77 |
| Price to book ratio | 0 | 0 | 2.40 | 1.60 | 0.90 | 0.58 | 0.37 | 0.39 | 0.31 | 0.68 | 2.32 | 1.99 | 2.07 | 2.28 | 1.23 | 2.56 | 1.49 | 1.10 | 1.32 | 1.06 |
| Price to sales ratio | 0 | 0 | 0.61 | 0.50 | 0.35 | 0.24 | 0.14 | 0.14 | 0.09 | 0.30 | 0.70 | 0.50 | 0.46 | 0.64 | 0.54 | 1.65 | 0.95 | 0.75 | 4.99 | 0.87 |
| Price to cash flow ratio | 0 | 0 | 17.40 | 16.91 | 6.42 | 0 | 3.53 | 0 | 2.27 | 0 | 0 | 21.79 | 7.52 | 4.81 | 2.22 | 8.30 | 20.06 | 13.44 | 36.95 | 10.20 |
| Enterprise value | 0 | 0 | 307Cr | 397Cr | 390Cr | 422Cr | 459Cr | 458Cr | 414Cr | 509Cr | 844Cr | 785Cr | 851Cr | 1324Cr | 909Cr | 2848Cr | 1979Cr | 1716Cr | 10498Cr | 1702Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 8.65 | 12.40 | 10.08 | 6.23 | 7.30 | 5.56 | 4.61 | 65.59 | 19.07 | 8.25 | 7.88 | 3.43 | 1.65 | 4.89 | 7.74 | 7.81 | 47.16 | 8.70 |
| Debt to equity ratio | 2.91 | 20.48 | 1.60 | 2.21 | 1.82 | 2 | 2.30 | 2.31 | 1.79 | 1.99 | 2.44 | 2.51 | 1.96 | 0.60 | 0.07 | 0 | 0.03 | 0.05 | 0.02 | 0.07 |
| Return on equity % | 49.93 | 64.12 | 32.58 | 13.92 | 7.71 | 3.86 | 2.75 | 0.92 | 1.78 | -33.45 | -20.72 | 2.57 | 14.07 | 69.69 | 56.11 | 42.87 | 12.64 | 9.60 | 8.62 | 6.13 |
IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio
The IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio is a key financial metric used by investors to evaluate IOL Chemicals & Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
IOL Chemicals & Pharmaceuticals Ltd (NSE: IOLCP, BSE: 524164) is currently trading at ₹194.31, with a market capitalization of ₹6202.24Cr. As a leading company in the Process industries sector and Chemicals: specialty industry, monitoring the IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio is essential for fundamental analysis.
IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio Current Value
The current IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio stands at 1.06.
The IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio Historical Trend
The IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio has shown the following historical trend:
- 2024: 1.06
- 2023: 1.32
- 2022: 1.10
- 2021: 1.49
- 2020: 2.56
The decline in IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio indicates improving financial efficiency or better earnings growth.
What IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio Indicates for Investors
The IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/B ratio shows how the market values company assets relative to book value.
IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio Analysis Summary
The IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of IOL Chemicals & Pharmaceuticals Ltd Price to Book Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.